Anonymous wrote:
The meningitis vaccine approved by the FDA in the US and given to all kids as part of routine vaccination schedules (unless kid has a vaccine-adverse parent who refuses to vaccinate due to lingering confusion over vaccines and autism, despite clear fraud from the author of the one positive study) is for meningococcal meningitis type A, which previously has accounted for the vast majority of meningococcal disease in the US. Meningococcal meningitis is devastating and can kill or permanently disable very rapidly, but the vaccine is very effective.
The problem is that two recent outbreaks at Princeton and UC Santa Barbara were a different type, type B, which is much more common in Europe and not the US. There is an approved vaccine used for B in Europe but the drug company never bothered to get approval here since so uncommon in the US. Once the two recent college outbreaks were shown to be type B, the European vaccine was brought in under special permission from the FDA and given to all Princeton and UC Santa Barbara students and their close contacts, and if these outbreaks continue, suspect the vaccine will be approved for use in the US more widely. Don't know yet if the Georgetown case is A or B. The student was not from the US and may not have been vaccinated against A. No students died at Princeton, but a contact of a Princeton student from Drexel did die last spring and she did have the same bug found previously at Princeton.
Yes, my understanding is that the tests are not yet complete. But the test they referred to was to determine whether it was bacterial or viral. I don't know if that is related to A vs B? Do you know, pp?